Prostate Cancer: Emerging Concepts. Part I

Annals of Internal Medicine

Volumn 125, Issue 2, 1996, Pages 118-125

  Garnick, Marc B ^a   Fair, William R ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

BLOOD; CANCER STAGING; CLASSIFICATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; HUMAN; IMMUNOLOGY; MALE; PATHOLOGY; PREDICTION AND FORECASTING; PROSTATE TUMOR; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; REVIEW; SURVIVAL; TIME; TREATMENT OUTCOME;

HUMANS; MALE; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; REFERENCE VALUES; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0030585988     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-125-2-199607150-00008     Document Type: Review

References (50)

1. Garnick MB. Prostate cancer: screening, diagnosis, and management. Ann Intern Med 1993;118:804-18.
2. Pienta KJ, Esper PS. Risk factors for prostate cancer. Ann Intern Med. 1993;118:793-803.
3. Kramer BS, Brown ML, Prorok PC, Potosky AL, Gohagan JK. Prostate cancer screening: what we know and what we need to know. Ann Intern Med. 1993;119:914-23.
4. Walsh PC. Using prostate-specific antigen to diagnose prostate cancer: sailing in uncharted waters [Editorial]. Ann Intern Med. 1993;119:948-9.
5. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin. 1996;46:5-27.
6. FDA approves test for prostate cancer. News release from the Food and Drug Administration. 29 August 1994.
7. Benson MC, Whang IS, Olsson CA, McMahon DJ, Cooner WH. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol. 1992;147:817-21.
8. Andriole GL, Telle WB, Coplen DE, Catalona WJ. PSA index (PSAI) as a predictor of prostate cancer in men with persistent serum PSA elevation [Abstract]. J Urol. 1992;147:387A.
9. Brawer MK, Aramburu EA, Chen GL, Preston SD, Ellis WJ. The inability of prostate specific antigen index to enhance the predictive value of prostate specific antigen in the diagnosis of prostatic carcinoma. J Urol. 1993;150:369-73.
10. Carter HB, Pearson JD, Metter EJ, Brant LJ, Chan DW, Andres R, et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA. 1992;267:2215-20.
11. Oesterling JE, Jacobsen SJ, Chute CG, Guess HA, Girman CJ, Panser LA, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific references ranges. JAMA. 1993; 270:860-4.
12. DeAntoni EP, Crawford ED. Prostate cancer awareness week: education, service and research in a community setting. Cancer 1996;75:1874-9.
13. Lilja H, Bjork T, Abrahamsson P, Stenman UH, Shaw N, Dowell B, et al. Improved separation between normals, BPH and carcinoma of the prostate by measuring free, complexed and total concentrations of prostate specific antigen [Abstract]. J Urol. 1994;151(Suppl):400A.
14. Christensson A, Bjork T, Nilsson O, Dahlen U, Matikainen MT, Cockett AT, et al. Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol. 1993;150:100-5.
15. Oesterling JE, Jacobsen SJ, Klee GG, Pettersson K, Piironen T, Abrahamsson PA, et al. Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. J Urol. 1995;154:1090-5.
16. Zinke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM. Long term (15 years) results after radical prostatectomy for clinically localized (stage T2C or lower) prostate cancer. J Urol. 1994;152:1850-7.
17. Murphy GP, Mettlin C, Menk H, Winchester DP, Davidson AM. National patterns of prostate cancer treatment by radical prostatectomy: results of a survey by the American College of Surgeons Commission on Cancer. J Urol. 1994;152:1817-9.
18. Walsh PC, Partin AW, Epstein J. Cancer control and quality of life following anatomical radical retropubic prostatectomy: results at 10 years. J Urol. 1994;152:1831-6.
19. Catalona WJ, Smith DS. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol. 1994;152:1837-42.
20. Bostwick DG, Myers RP, Oesterling JE. Staging of prostate cancer. Sem Surg Oncol. 1994;10:60-72.
21. Paulson DP. Impact of radical prostatectomy in the management of clinically localized disease. J Urol. 1994;152:1826-30.
22. Morton HM, Steiner PL, Walsh PC. Cancer control following anatomical radical prostatectomy: an interim report. J Urol. 1991;145:1197-200.
23. Calciano R, Chodak GW, Garnick MB, Kuban DA, Resnick MI, Pinkowish M. The prostate cancer conundrum. Patient Care. 1995;29:84-104.
24. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol. 1993; 150:110-4.
25. Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh PC. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am. 1991;20:713-25.
26. Kleer E, Larson-Keller JJ, Zincke H, Oesterling JE. Ability of preoperative serum prostate-specific antigen value to predict pathologic stage and DNA ploidy. Influence of clinical stage and tumor grade. Urology. 1993;41:207-16.
27. Chybowski FM, Keller JJ, Bergstralh EJ, Oesterling JE. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters. J Urol. 1991;145:313-8.
28. Johannson JE, Adami HO, Andersson SO, Bergstrom R, Holmberg L, Krusemo UB. High 10-year survival rate in patients with early, untreated prostatic cancer. JAMA. 1992;267:2191-6.
29. Garnick MB. The dilemmas of prostate cancer. Sci Am. 1994;270:52-9.
30. Fleming C, Wasson JH, Albertsen PC, Barry MJ, Wennberg JE. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. Prostate Patient Outcomes Research Teams. JAMA. 1993;269:2650-8.
31. Chodak GW, Thisted RA, Gerber GS, Johansson J, Adolfsson J, Jones GW, et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med. 1994;330:242-8.
32. Litwin MS, Hays RD, Fink A, Ganz P, Leake BL, Leach GE, et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA. 1995;273:129-35.
33. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. Long-term survival among men with conservatively treated localized prostate cancer. JAMA. 1995;274:626-31.
34. Whitmore WF Jr. Consensus Development Conference on the Management of Clinically Localized Prostate Cancer. Overview: historical and contemporary. NCI Monogr. 1988:7-11.
35. Epstein JI. Evaluation of radical prostatectomy capsular margins of resection. The significance of margins designated as negative, closely approaching, and positive. Am J Surg Pathol. 1990;14:626-32.
36. McNeal JE, Villars AA, Redwine EA, Freiha FS, Stamey TA. Capsular penetration in prostate cancer. Significance for natural history and treatment. Am J Surg Pathol. 1990;14:240-7.
37. van den Ouden D, Bentvelsen FM, Boeve ER, Schroder FH. Positive margins after radical prostatectomy: correlation with local recurrence and distant progression. Br J Urol. 1993;72:489-94.
38. Ohori M, Wheeler TM, Kattan MW, Goto Y, Scardino PT. Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol. 1995;154:1818-24.
39. Frohmuller HG, Theiss M. Radical prostatectomy in the management of localized prostate cancer. Eur J Surg Oncol. 1995;21:336-40.
40. Stein A, deKernion JB, Smith RB, Dorey F, Patel H. Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer. J Urol. 1992;147:942-6.
41. Vieweg J, Rosenthal FM, Bannerji R, Heston WD, Fair WR, Gansbacher B, et al. Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Cancer Res. 1994;45:1760-5.
42. Eisbruch A, Perez CA, Roessler EH, Lockett MA, et al. Adjuvant radiation after prostatectomy for carcinoma of the prostate with positive surgical margins. Cancer. 1994;73:384-8.
43. Lange PH, Lightner DJ, Medini E, Reddy PK, Vessella RL. The effect of radiation therapy after radical prostatectomy in patients with elevated prostate specific antigen levels. J Urol. 1990;144:927-32.
44. Fleshner N, Fair WR. Anti-androgenic effects of combination of finasteride plus flutamide in patients with prostatic carcinoma. Br J Urol. 1996; [In press].
45. Fleshner NE, Trachtenberg J. Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side effects. J Urol. 195;154:1642-6.
46. Klotz LH, Herr HW, Morse MJ, Whitmore WF Jr. Intermittent endocrine therapy for advanced prostate cancer. Cancer. 1986;58:2546-50.
47. Russo P, Ligouri G, Huryk R, Yang CR, Heston WD, Fair WR, et al. Effect of intermittent estrogen administration on the R3327H rat prostatic carcinoma. Surgical Forum. 1986;37:654-6.
48. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA. 1993;270:948-56.
49. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994;271:368-74.
50. Dugan JA, Bostwick DG, Myers RP, Qian J, Bergstralh EJ, Oesterling JE. The definition and preoperative prediction of clinically insignificant prostate cancer. JAMA. 1996;275:288-94.